SCHEMBL17835255

SCHEMBL17835255

CCC1CCCC(C(=O)OC)C1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.42
CHRNB2 P17787 2/20 0.40
CHRNA4 P43681 2/20 0.40
CHRNB4 P30926 1/20 0.40
CHRNA3 P32297 1/20 0.40
CHRNA7 P36544 1/20 0.40
GAA P10253 1/20 0.39
CHRM2 P08172 1/20 0.39
CHRM4 P08173 1/20 0.39
CHRM3 P20309 1/20 0.39
TP53 P04637 1/20 0.37
EPHX1 P07099 1/20 0.36
POLB P06746 1/20 0.36
ANPEP P15144 1/20 0.36
DPP4 P27487 1/20 0.36
DPP8 Q6V1X1 1/20 0.36
DPP9 Q86TI2 1/20 0.36
DPP7 Q9UHL4 1/20 0.36
MEN1 O00255 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9633431 0.89 ALDH1A1 (0.43) ALDH1A1SMN1; SMN2CHRNB2CHRNA4CHRNB4
SCHEMBL5888214 0.88 CHRNB2 (0.42) ALDH1A1SMN1; SMN2CHRNB2CHRNA4CHRNB4
SCHEMBL12055465 0.88 CHRNB2 (0.42) ALDH1A1SMN1; SMN2CHRNB2CHRNA4CHRNB4
SCHEMBL14296565 0.88 CHRNB2 (0.42) ALDH1A1SMN1; SMN2CHRNB2CHRNA4CHRNB4
SCHEMBL13163204 0.87 ALDH1A1 (0.42) ALDH1A1SMN1; SMN2CHRNB2CHRNA4CHRNB4
SCHEMBL351586 0.87 ALDH1A1 (0.42) ALDH1A1SMN1; SMN2CHRNB2CHRNA4CHRNB4
SCHEMBL351587 0.87 ALDH1A1 (0.42) ALDH1A1SMN1; SMN2CHRNB2CHRNA4CHRNB4
SCHEMBL351588 0.87 ALDH1A1 (0.42) ALDH1A1SMN1; SMN2CHRNB2CHRNA4CHRNB4
SCHEMBL22796405 0.85 MEN1 (0.50) ALDH1A1SMN1; SMN2POLBMEN1KMT2A
SCHEMBL13593205 0.85 ALDH1A1 (0.41) ALDH1A1SMN1; SMN2CHRNB2CHRNA4CHRNB4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230128198-A1 NOVEL HETEROCYCLIC COMPOUNDS USEFUL AS AURORA A SELECTIVE INHIBITORS JACOBIO PHARMACEUTICALS CO., LTD (CN) 2023-04-27 US disclosed
WO-2016100281-A1 INDOLE AND AZAINDOLES DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES MERCK PATENT GMBH (DE) 2016-06-23 WO disclosed
US-20160168090-A1 NOVEL INDOLE DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES MERCK PATENT GMBH (DE) 2016-06-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160168090-A1 NOVEL INDOLE DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES P2RX3, P2RX7, P2RX2 ALDH1A1 2404/4885SMN1; SMN2 1322/4885CHRNB2 64/4885
US-20230128198-A1 NOVEL HETEROCYCLIC COMPOUNDS USEFUL AS AURORA A SELECTIVE INHIBITORS AURKA, AURKC, AURKB ALDH1A1 2071/4885SMN1; SMN2 4569/4885CHRNB2 3987/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.